Accelerated Senescence of Cancer Stem Cells: A Failure to Thrive or a Route to Survival? by Erenpreisa, Jekaterina et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 4
Accelerated Senescence of Cancer Stem Cells: A Failure
to Thrive or a Route to Survival?
Jekaterina Erenpreisa, Kristine Salmina and
Mark Steven Cragg
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/intechopen.68582
Abstract
Accelerated senescence of cancer stem cells (CSCs) represents an adaptive response allow-
ing withstand cell death. TP53, the pivotal tumor suppressor plays an important role in this 
process by inducing a prolonged dual state with senescence and self-renewal as potential 
outcomes. Molecularly, this is achieved by activating both OCT4A (POU5F1) and p21CIP1. 
OCT4A suppresses the excessive activity of p21 preventing the immediate precipitation of 
apoptosis or terminal senescence. It persists as long as sufficient cellular energy remains; 
generated through autophagy, itself sequestrating p16INK4A in the cytoplasm. As such, 
autophagic capacity is the bottleneck of these TP53-dependent senescence reversal processes, 
as well terminal senescence will follow if DNA damage is not ultimately repaired. In TP53 
mutants the CSC-like state is boosted by stressed cells overcoming the tetraploidy barrier. 
These cells acquire additional DNA repair capacity through mitotic slippage and entrance 
to a sequence of ploidy cycles, allowing repair and sorting DNA damage, ultimately facili-
tating the genesis of mitotically competent daughter cells following final depolyploidisa-
tion. Again, autophagy is required to fuel this process. More detailed knowledge of these 
arcane processes anticipates the provision of anti-cancer drug targets, such as AURORA 
B kinase and Survivin, which ensure mitotic slippage and the continuity of ploidy cycles.
Keywords: accelerated senescence, cancer stem cells (CSCs), TP53, DNA damage, self-
renewal OCT4A (POU5F1), p21CIP1, pluripotency, apoptosis, metastability, DNA repair, 
autophagy, p16INK4A, tetraploidy, ploidy cycles, AURORA B, Survivin, AMPK
1. Introduction
In 2001 Roninson and colleagues [1] published the now seminal article entitled “If not apoptosis, 
then what? Treatment-induced senescence and mitotic catastrophe in tumor cells”. After decades 
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of overwhelming attention toward apoptosis induction as the cure for cancer, this article gave 
birth to a new field in cancer research. They wrote: “Inhibition of the program of apoptosis has 
been reported to have little or no effect on clonogenic survival after treatment with drugs or 
radiation in several tumor cell lines. A decrease in apoptosis is compensated in such cell lines by 
an increase in the fractions of cells that undergo permanent growth arrest with phenotypic fea-
tures of cell senescence. The senescent phenotype distinguishes tumor cells that survived drug 
exposure but lost the ability to form colonies from those that recover and proliferate after treat-
ment. Although senescent cells do not proliferate, they are metabolically active and may produce 
secreted proteins with potential tumor-promoting activities.”
Since that article, the induction of senescence was even claimed as the new goal of cancer 
treatment [2] and many researchers stepped on this path.
In this chapter, we describe our data over the last 2 decades, which along with other research, 
substantiates the exact opposite: that so-called accelerated cell senescence (ASC) (also called 
stress-induced premature senescence) and mitotic catastrophe (MC) are not desired goals of 
cancer treatment. Rather, we show that these processes can enable genotoxically treated can-
cer cells to escape cell death, not only by secretion of survival promoting components [3] but 
also by effective DNA repair. By stabilizing or recovering the innate stem properties of cancer 
stem cells (CSCs) senescence can be reversed by DNA damaged-induced ACS. To explore 
these concepts clearly it is first important to review and define the typical features of cell 
senescence and the biology of CSCs.
2. Biological features of cell senescence: what is clear and what is not?
Replicative senescence is usually dependent on TP53/p21CIP1/pRb/E2F pathway, whereas 
accelerated senescence can be mediated through TP53/p21CIP1/pRb/E2F or, p16ink4a/pRb/
E2F pathway or both [4]. Cells acquire flat morphology, upregulate autophagy, and become 
positive for sa-β-galactosidase (pH 6.0) staining, indicative of high lysosomal activity. Erosion 
of telomeres and achievement of the Hayflick limit characterizes proliferative senescence, 
while in ACS the telomeres are not shortened [5]. However, the emergence of DNA strand 
breaks and the resulting DNA damage response (DDR) characterizes both proliferative and 
accelerated senescence [6]. Persistent irreparable DNA damage triggers the senescence-asso-
ciated secretome [7], which is another feature of cell senescence. Emergence of endopolyploid 
cells, some capable of escaping senescence is also a typical feature of normal [8] and cancer 
cells [9, 10]. The reversibility of genotoxically induced senescence coupled to reversible poly-
ploidy and its relation to stemness and population recovery are key phenomenon to under-
stand if we wish to develop better cancer treatments [11–17]. The polyploidy component of 
senescence is associated with resistance to chemotherapy and involves mTOR activation; its 
inhibition causes senescence reversal, neo-expression of stem cell markers [18] and increased 
resistance of cancer cells to chemotherapy [19]. However, whether any senescing primary 
somatic cancer cell is capable of displaying the above features associated with senescence 
reversal or whether this only applies to cancer stem cells (CSCs) and how the recovery finally 
occurs is still largely unclear.
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3. The common biological features of embryonic stem cells (ESCs) 
and CSC
It is now generally accepted that CSCs play a central role in cancer genesis and promotion. 
Firstly, they possess the developmental potential, being capable of sphere formation and the 
ability to differentiate into mesoderm, endoderm and ectoderm progenies. Many gene mod-
ules of ESC are found active in various cancers [20], in turn, aggressive tumors express the 
markers of ESC or germ cells [21–24]. Third, tumors also acquire epigenetic profiles of ESC 
under genotoxic [25–28] or hypoxic conditions [29], in association with overcoming the tet-
raploidy barrier. So, epigenetically, CSCs of highly de-differentiated tumors possess many 
features of ESC.
Epigenetic instability is another notable feature of ESC and likely also of CSC. ESCs pos-
sess ‘poised’, chromatin marking of key developmental genes. Such marking consists of large 
regions of H3 lysine 27 methylation harboring smaller regions of H3 lysine 4 methylation. 
These domains tend to coincide with genes of transposable elements (TE) expressed at low 
levels [30]. Some activity of TE may provide the transcriptional noise, which is necessary for 
the fate changes observed during early embryo development [31, 32]. Moreover, the enhanc-
ers in ESCs are enriched for the transposable elements and genetic variations associated with 
cancer [33].
An additional peculiarity of ESC (and likewise CSC) is the absence of the cell cycle G1/S 
restriction checkpoint: here OCT4 and NANOG activate cyclin D kinases cdk4 and cdk6 
[34] to force ESC into S-phase. Therefore, damaged ESC cells typically accumulate in the G2 
DNA damage checkpoint instead, whose relative weakness allows mitotic slippage [35, 36]. 
Moreover, stressed ESC and likely also CSC possess a peculiar intermediate post-slippage 
phase (not 4 N-G1) [37, 38] containing non-degraded cyclin B1, which is normally destroyed 
after mitosis. In irradiated lymphomas and HeLa cells this nondegraded cyclin B1 was found 
to be sustained by activated Mos kinase [39]. Some additional activators of meiotic prophase 
were also revealed [40, 41] indicating a possible trigger from the mitotic DNA damage check-
point into a meiotic prophase-like state with its more effective recombination checkpoint. 
Potentially, this meiosis-like molecular setting allows CSCs to tolerate both DNA damage and 
tetraploidy and use this compartment for DNA repair by homologous recombination [14, 42]. 
All three facets of CSC biology; poised chromatin, an epigenetic shift to embryonality, and the 
peculiar cell cycle checkpoints are apparently interrelated and involved in ACS, whose main 
hallmark is persistent DNA damage. The remainder of this chapter is an attempt to assess this 
notion within our experimental material.
4. Accelerated senescence of human fibroblasts induces senescing 
tetraploid cells with transient self-renewal potential
In one of our recent experimental systems, embryonal lung human fibroblasts (IMR90 cells) 
were grown in normoxia (20%) and 5% CO
2
 and reached full senescence (proliferative arrest 
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with zero mitotic index) after 32–34 passages. Senescence was characterized by flat morphology 
of enlarged cells, nuclear positivity of p21CIP1 and cytoplasmic accumulation of p16INK4A; 
at the terminally stage nuclei were swelling and p16 entered the cell nuclei [43]. DNA cytom-
etry revealed an accumulation of a portion of the prematurely senescing cells in the G2 com-
partment (Figure 1A, B) which were also overcoming the tetraploidy barrier with formation 
of a few (4–6%) tetraploid cells, which sometimes entered aberrant mitoses. These cells with 
large polyploid nuclei began to express both senescence markers (p21CIP1 and p16INK4A) 
with the self-renewal marker NANOG; these cells were also positive for DNA double strand 
breaks (DSB) (Figure 1C–F). The acquisition of bi-potentiality by a small proportion of normal 
Figure 1. Characteristics of IMR90 human embryonal fibroblasts undergoing pre-senescence. Cells were cytospun, fixed 
and stained for DNA image cytometry. DNA content was determined for at least 200 cells in each condition and is 
represented as the percentage in a state of (A) logarithmic growth; (B) presenescence with some accumulation of cells in 
the G2M (4C) checkpoint and some increase of >4C DNA cell numbers. (C) shows the results from immunofluorescence 
studies staining for γ-H2AX, NANOG, P21CIP1 or p16INKA4A proteins with positive staining discriminated with 
respect to nuclei size; (D–F) – typical immunofluorescence patterns showing combinations of self-renewal (NANOG) 
and senescence (p21CIP1 and p16INK4A) markers in the same cells with large (>4C nuclei as measured by DAPI) nuclei, 
and positivity for DSBs γ-H2AX. Bars= 10 μm. Republished from Ref. [43].
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cells overcoming the G2M DNA damage checkpoint is reminiscent of stem cell activity; with 
the same lack of arrest in the G1/S checkpoint and weak G2M checkpoint. Nevertheless, these 
cells did not persist in the culture and NANOG expression was lost in later passages.
These observations heightened our interest in the role of senescence in the CSC model.
5. Ovarian germline cells challenged by genotoxic stress display the dual 
p53-dependent expression of p21CIP1 and OCT4A
As a model for CSC we chose the ovarian germline cancer cells PA1. These cells are wt TP53, 
possessing features of embryonal carcinoma [44]. They were treated with etoposide (ETO), the 
inhibitor of Topoisomerase II, to induce DSB through the impairment of S-phase [45]. Cells 
entered massive, prolonged, G2-arrest, acquired flat morphology, and signaled persistent 
DDR for about 4–5 days in nearly 100% of cell nuclei (positive for γ-H2AX and CHK2 foci) 
with some cells overcoming the tetraploid barrier (Figure 2A, B). The most surprising fact was 
that regulators of the opposing processes of senescence (p21CIP1) and self-renewal OCT4A 
(POU5F1) were highly induced in the same G2-arrested cells (Figures 2C and 4A). This was 
downstream of activated TP53, as both p21 and partly OCT4A became downregulated after 
TP53 RNAi silencing (Figure 2C) [45]. Further study [46] revealed that p53-activated OCT4A 
down-regulated p21CIP1, moderating its expression and preventing cells from precipitat-
ing terminal senescence or apoptosis (Figure 2D), thus providing the opportunity for repair. 
Downregulation of p21 via OCT4 was previously shown in ESC [47].
Moreover, such stress-activated OCT4A was transiently disconnected from its self-renewal 
partners (SOX2 and NANOG), as those protein levels were low and/or not activated 
alongside Oct4A [46]. Therefore, the autoregulatory and feedforward loops seen in ESC 
[48] were not present, potentially due to the known down-regulation of the Nanog gene 
promoter by activated p53 [49] and/or the down-regulation of NANOG by high levels of 
OCT4A [50]. However, it is also possible that another, Cdk4-activating function of OCT4A 
[34] could be enhanced, while inhibiting action of p21on Cyclin D/cdk4,6 checkpoint func-
tion reduced forcing escape of the damaged cells from G1/S checkpoint leading to their 
accumulation in G2-arrest. Figure 3 presents these hypothetical relationships between the 
cell cycle and pluripotency functions of stress-activated OCT4A induced by DNA damage 
through activated p53.
The bizarre duality of OCT4A with p21CIP1 was subdued and cell cycle in the PA1 clones 
returned to normal, on days 7–14 (Figure 2A), while silencing of stress-activated OCT4A pre-
vented recovery [46]. This transient undecided state in G2 arrest, between true senescence and 
true self-renewal, was thus lasting as long as wtTP53 was activated by the DNA DSB.
In accordance with our findings in PA1 cells after ETO treatment, a recent high-throughput 
RNAi screen revealed the intrinsic roles of S and G2, functionally establishing that pluripo-
tency control is hardwired to the cell-cycle machinery and that the ATM/ATR-CHEK2-p53 axis 
enhances the TGF-b pathway to prevent premature cell death [36]. As well, [3] showed that 
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cellular senescence accompanying DNA damage or DNA damage as such favors cell repro-
gramming in vivo models. It should be noted however, that the frequency (chance) of survival 
in our PA1-ETO model was not high. It stresses the importance of another possible player in 
this “undecided” stage between senescence and self-renewal, of transcriptional noise.
Figure 2. Response of PA -1 cells to ETO treatment. PA -1 cells were treated with 8 μM ETO for 20 h, then washed and 
assessed at the indicated time point. (A) Cells were cytospun, fixed and stained for DNA image cytometry as previously 
described [46]. DNA content was determined for at least 200 cells in each condition and is represented as a percentage. 
Profound G2 arrest on day 2 was observed followed by the simultaneous emergence of a polyploid (>4C) and 4nG1 
fraction on day 5 before the recovery of the normal cell cycle profile by day 7. (B) The proportion of pCHK2-positive 
cells was examined in the context of DNA content with cells sub-divided into small or large cells. In the NT control 
sample, all cells were pCHK2-negative with an expected nuclei size distribution (2C 80%; ≥ 4C 20%). On day 2, all cells 
were pCHK2-positive and the vast majority of nuclei were large (≥4C). By day 5, cells with small nuclei appeared, all 
of which were pCHK2-negative. Data are representative of>three independent experiments; (C) Immunoblot analysis 
of TP53, OCT4A and P21CIP1 in PA-1 cells after ETO treatment. PA-1 cells were treated with non-target (ntg) siRNA 
(−) or siRNA-TP53 (+) for 24 h before treatment with 8 μM ETO, washing after 20 h and cell lysates made and assessed 
by immunoblotting for p53, P21CIP1, OCT4A or GAPDH as a loading control at the indicated time-points (day 3 and 
5). p53 was upregulated in response to ETO treatment and suppressed by siRNA-TP53. P21CIP1 and OCT4A were 
also upregulated by ETO treatment, and the upregulation was restricted by treatment with siRNA-TP53. Data are 
representative of three independent experiments. (A–C) republished from Ref. [45]. (D) OCT4A suppresses p21CIP1 and 
induces senescence. PA-1 cells were treated with ntg-siRNA or OCT4-siRNA for 24 h before treatment with 8 μM ETO for 
20 h and replacement with fresh media. Protein expression was assessed at the indicated time points by immunoblotting. 
Cell lysates were made and assessed by immunoblotting for pCHK2, RAD51, p53, p21CIP1, OCT4A and GAPDH as a 
loading control. Republished from Ref. [46].
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6. Transient bi-potentiality of CSC for senescence and self-renewal 
displays the population features of “noisy” expression and activated 
transposable elements
One of the interesting facets of this dual expression of self-renewal and senescence regulators 
in the PA1-ETO model was the high heterogeneity in response, with individual cells express-
ing wildly differing levels of OCT4 and p21 (Figure 4A). This explorative chaos continued for 
4–6 days and culminated with massive cell death selecting a small proportion (<1%) of resis-
tant survivors. Earlier studies on ESC observing the extensive heterogeneity and fluctuations 
of gene expression in individual stem cells led the authors to suggest that “noise “may be the 
central driving force behind multipotency [32, 50, 52].
Therefore, notably, a similar long ‘stochastic’ phase of choice between senescence and self-
renewal (initiated by activating DNA repair and mesenchymal to epithelial transition), with 
Figure 3. Schematic of the response of wt TP53 cancer stem cells to genotoxic damage. P53 is activated and simultaneously 
induces p21CIP1 and OCT4A. OCT4A moderates the expression of p21CIP1 preventing apoptosis or terminal senescence 
[45, 46]. Activated p53 also downregulates the promoter of Nanog gene [49]. Therefore, the multipotency circuit based 
on Nanog stimulation of OCT4A and SOX2 [48] (dashed lines) is interrupted. In addition, the overexpressed OCT4A 
also down-regulates NANOG [50]. Activated OCT4A also enhances the activity of cdk4 and favors cells exit from 
the G1/S restriction checkpoint [34] and accumulation in G2. Activated p53 also activates pAMPK, likely via OCT4A. 
pAMPK activates autophagy. Functional autophagy sequesters and digests p16INKA4 within the cytoplasm, preventing 
its transition into the cell nuclei and hence terminal senescence. With exhaustion of autophagic capacity (halting of 
autophagic flux) pAMPK activates a metabolic checkpoint [51], which precipitates cell death in the G1 and possibly also 
G2 cell compartments.
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Figure 4. Population heterogeneity in expression of OCT4A and p21CIP1 in response of PA1 cells to ETO treatment. 
(A) Population heterogeneity in expression of OCT4A and p21CIP1 is extended for days 2–6 post ETO treatment, 
before recovery from day 7, when it reduces; (B) Population heterogeneity is accompanied by a degree of polyploidy as 
represented by DNA histograms on day 4, with underreplication of the cells in late S-phase of diploid and polyploid cell 
cohorts; this phenomenon is enhanced after impediment of autophagic flux. Republished from Ref. [46].
Senescence - Physiology or Pathology52
heterogenous activation of pluripotency genes, preceding the period of further determination 
of self-renewal circuitry has also been reported during the induction of pluripotent stem cells 
[53].
Our study of DNA histograms in ETO-treated PA1 cells revealed in addition to G2M arrest, a 
strong under-replication in late S-phase (Figure 4B), the time of constitutive heterochromatin 
replication [46]. Similarly, arrest in late S- and G2M phase was reported after Doxorubicin 
treatment in p53 mutant cancer cells [54]. This feature may therefore be equally required 
for any senescence causing release from silencing and subsequent activation of TE nested in 
constitutive heterochromatin as retrotransposition was found in replicative cell senescence 
[55, 56]. In particular, under-replication may cause de-repression of TE genes and result in 
the epigenetic activation of the developmental genes in the poised chromatin regions [30] 
enabling the reprogramming by senescence. Indeed, we observed the activation and clus-
tering of ALU elements in the ETO treated PA1 cells [57]. The initial de-repression of trans-
posons could provide the necessary “noisy” background of transcription allowing chaotic 
fluctuations of gene expression, which enable stochastic choice of the appropriate attractors 
for cell fate change and escape from terminal senescence.
7. The role of autophagy in preventing terminal senescence
Our further observations in the PA1 model showed the importance of autophagy in with-
standing the proteotoxic stress following ETO treatment and its crucial role in maintain-
ing viability; inhibition of autophagy culminated in chromatin fragmentation and nuclei 
disintegration [46, 57]. Stress-activated OCT4A mainly colocalized, and correlated in its 
nuclear concentration in individual cells, with activated AMPthr172 kinase (Figure 5A, B). 
AMP-activated protein kinase (AMPK) serves as a general energy depletion sensor and acti-
vator of autophagy. The energy stress-response of AMPK is also tightly linked to the DDR 
of p53 [58, 59] and can induce a p53-dependent glucose-sensitive metabolic checkpoint [51] 
precipitating apoptotic cell death from the G1/S and likely autophagic death from G2M 
checkpoint [60].
We found, in addition, that active autophagy in PA1-ETO cells sequestered p16INK4A aggre-
somes within the autophagic vacuoles (Figure 5C i–ii), while disability of autophagy enabled 
p16 diffuse distribution in the cell nuclei and caused terminal senescence with nuclear dis-
integration (Figure 5 iii-iv) preventing survival of ETO-treated cells [46]. The p53-dependent 
role of AMPK, its relationship with stress-activated OCT4A, and the role of autophagy in the 
prevention of terminal senescence for TP53 wild-type CSC cells is schematically presented in 
Figure 3.
However, in TP53 mutants, the cells find an additional pathway for potential recovery – 
they undergo mitotic slippage and employ polyploidy for repair and sorting the damaged 
DNA.
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Figure 5. Autophagic response of PA1 cells to ETO-mediated DNA damage: (A) Scatterplot of image cytometry 
of OCT4A and pAMPK in individual cells assessed on day 4 after ETO treatment. There is a clear correlation 
between enhanced expression of OCT4A and pAMPKThr172 of ETO-treated cells; (B) OCT4A and pAMPKThr172 
immunofluorescence in PA-1 cells 4 days after ETO-treatment. (C) The relationship between autophagy and 
senescence. PA1-ETO cells were treated without or with Bafilomycin A1, prior to media being removed and 
replaced with fresh media; cells were harvested 48 h later (day 4). (i) imunofluorescent staining for p16ink4a, 
LAMP2 or DAPI as shown via the BRG optical filter, (ii) only LAMP2 demonstrating high level of functional 
autophagy sequestrating p16ink4a-containing aggresomes. (iii–iv) shows an example of autophagic failure, where 
sequestration of p16ink4a is partly lost, diffusing into the cytoplasm and nucleus, which is destroyed. Bars = 10 μm. 
Republished from Ref. [46].
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8. TP53 mutants with persistent DNA damage undergo mitotic slippage, 
ploidy cycles, and are capable of reversing senescence alongside 
polyploidy
Some authors have reported that genotoxically treated cancer cells can paradoxically 
combine sa-β-gal-positivity (considered as a universal marker of senescence) with expres-
sion of Ki67, a hallmark signature of proliferation. This “swing phenotype” is apparently 
dependent on p21 and TERT [61]. Others have reported that sa-β-gal-positivity is also 
compatible with polylploid cells (induced by DNA chemotherapy) undergoing de-poly-
ploidization and surviving [13, 16]. Overcoming the tetraploidy barrier in TP53 mutants, 
boosting the self-renewal network [25, 26] – can likely convert tumor cells into CSCs or 
stabilize them. Moreover, paradoxically, genotoxically challenged TP53 mutant tumor 
cells, which uncouple DNA replication from cell division and undergo mitotic slippage 
possessing both DNA DSBs and Ki67 expression (Figure 6A). As well the mitotic chromo-
Figure 6. Mutant TP53 tumors have additional options for repair and sorting of DNA damage in ploidy cycles. The 
genotoxic damage in mutant TP53 cancer cell lines of various origins favors mitotic slippage with exaggerated: (A) 
H3ser10 activation by mitotic AURBK and (B) expression of proliferation marker Ki67 tolerating DNA damage detected 
by γ-H2AX foci. This is followed by (C) DNA damage sorting by micronuclei in the next mitosis of the polyploid cells 
and/or (D) by expelling and autophagic digestion of the whole subnuclei of multi-nucleated cells. (A) HeLa cells, 10 Gy 
irradiation, day 4; (B) MDA MB 231 breast cancer cells on day 4 after 100nM Doxorubicin treatment (in collaboration 
with A. Boiko); (C) SK-Mel-28 cell, 30Gy, day 2 (in collaboration with TR Jackson); (D) WI-L2-NS lymphoblastoma, 
10Gy, day 6. Republished from Ref. [62]. Bars (A)=20 μm; (B–D)=10 μm.
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some passengers, such as catalytically active Aurora B kinase (Figure 6B) and Survivin 
are expressed during mitotic slippage and in resulting polyploidy interphase [19, 63, 64]. 
Notably, activated AMPK, responsible for the metabolic aspect of senescence-associated 
autophagy, also possesses these same chromosome passenger features [65]. All of these 
observations indicate that stress-induced “senescent” cancer cells retain their proliferation 
potential through induced polyploidy coupled to active autophagy. During this process 
or/and in the next tetraploid/octaploid cell cycle they can additionally repair DNA [42] 
and also sort the un-repaired DNA damage in micronuclei (Figure 6C), as first reported by 
Haaf et al. [66]. The autophagic nature of this sorting found by Rello-Varona et al. [67]; has 
been reviewed previously in Ref. [68]. This sorting of the DNA damage through micronu-
cleation was observed by us in several tumor cell line models after different kinds of geno-
toxic treatments as exemplified in Figure 6 (A–C). The autophagic elimination of large 
DNA portions or whole sub-nuclei with damaged DNA was also observed (Figure 6D) 
[62, 68, 69] as another intriguing feature of the late post-damage events of genotoxically 
treated TP53 mutants.
All this indicates that TP53 mutants have a strong capacity for surviving genotoxic damage 
and reversing cell senescence by reversible endopolyploidy through a pathway involving 
boosted stemness. This pathway is in fact far away from the regulations of the typical mam-
malian cell cycle. More likely, these tumor cells exploit the life-cycle-like regulations of the 
unicellular organisms recapitulated from evolutionary ploidy cycles as we have postulated 
previously in Refs. [70, 71] and showed recently by bioinformatics study of polyploidy [72]. 
It only remains to add that in general tumor cells cannot bear wild type TP53 and inactivate 
it, if not by mutations, then in many other ways [73]. Perhaps the increased ability to access 
additional routes to cell survival by overcoming senescence and repairing DNA damage as 
detailed above, also help explain this inactivation of TP53 function in tumors.
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